Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In Vivo

Allen Clermont
Director, Pre-clinical Pharmacology
KalVista Pharmaceuticals, Cambridge, MA USA

July 1, 2022
Disclosure:

E: All authors are employees of KalVista Pharmaceuticals
Introduction

- Hereditary angioedema (HAE) is a genetic disorder that causes recurrent episodes of tissue swelling in the skin and mucosal membranes with a prevalence of approximately 1:50,000\(^1\).
- HAE attacks are caused by uncontrolled plasma kallikrein activity resulting in increased bradykinin (BK) generation, vascular permeability and inflammation\(^2\).
- FXIIa inhibition has been implicated as a novel therapeutic target to prevent the generation of BK in HAE\(^3\).
- Carrageenan-induced paw edema has been used as a preclinical model of bradykinin-mediated angioedema to investigate potential treatments for HAE\(^4\).

Purpose

This study evaluated the effects of the oral FXIIa inhibitor KV998086 in carrageenan-induced kallikrein-kinin system activation and angioedema in mice.
Potency and selectivity of FXIIa inhibitor KV998086

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>KV998086 IC$_{50}$ nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor XIIa</td>
<td>10.0</td>
</tr>
<tr>
<td>Factor Xa</td>
<td>&gt;40000</td>
</tr>
<tr>
<td>Plasma Kallikrein</td>
<td>&gt;40000</td>
</tr>
<tr>
<td>Thrombin</td>
<td>&gt;40000</td>
</tr>
<tr>
<td>Plasmin</td>
<td>&gt;40000</td>
</tr>
<tr>
<td>Trypsin</td>
<td>&gt;40000</td>
</tr>
</tbody>
</table>

- KV998086 was selected from a portfolio of potent and selective oral FXIIa inhibitors for *in vitro* and *in vivo* preclinical pharmacology
- KV998086 is highly potent and selective for FXIIa compared to closely related serine proteases
Effects of FXIIa inhibitor KV998086 on dextran sulfate stimulated kininogen (HK) cleavage and plasma kallikrein (PKa) generation in human plasma

Pretreatment of human plasma with KV998086
- Inhibits HK cleavage with an IC$_{50}$ = 81 nM
- Blocks the activation of plasma prekallikrein (PK) to PKa
Oral KV998086 pharmacokinetic profiles

- KV998086 has high oral bioavailability in rat and dog (>70%)
- The IC$_{50}$ of KV998086 for the inhibition of HK cleavage in DXS-stimulated human plasma is indicated by the green lines
Carrageenan (CG)-induced paw edema in mice

Experimental Design

- Oral KV998086 protects mice from CG induced paw edema
- KV998086 is as effective as FXII gene knockout in this model
Effects of oral KV998086 on CG-induced kallikrein kinin system activation and HK cleavage in plasma

- Carrageenan (CG) stimulates HK cleavage and increases FXIIa and PKa
- Oral KV998086 protects mice from HK cleavage in a dose responsive manner
Effects of orally KV998086 upon CG-induced generation of FXIIa and PKa

- KV998086 protects mice from PKa and FXIIa generation in a dose-responsive manner
- Oral KV998086 is as effective as FXII gene knockout in protecting mice from CG induced kallikrein kinin system activation
Summary/Conclusions

• KV998086 is a novel potent, selective, and orally available FXIIa inhibitor
  – FXIIa IC$_{50}$ is 10nM and highly selective compared with related serine proteases
  – The IC$_{50}$ for DXS-stimulated HK cleavage in whole human plasma is 81 nM
  – High oral bioavailability demonstrated in both rat and dog

• Preclinical studies in the mouse model of carrageenan induced angioedema showed:
  – KV998086 protected mice from paw edema comparable to FXII knockout
  – KV998086 inhibited the generation of FXIIa & PKa and HK cleavage in a dose-responsive manner

• Oral KV998086 may provide a therapeutic opportunity to block kallikrein-kinin system activation and prevent angioedema attacks in HAE
Thank you

Authors:

Allen C Clermont\textsuperscript{1}, Daniel Lee\textsuperscript{1}, Nivetha Murugesan\textsuperscript{1}, Hannah J Edwards\textsuperscript{2}, Stephen J Pethen\textsuperscript{2}, Edward J Duckworth\textsuperscript{2}, Sally L Hampton\textsuperscript{2} and Edward P Feener\textsuperscript{1}.

KalVista Pharmaceuticals: \textsuperscript{1}Cambridge MA, USA, \textsuperscript{2}Salisbury, UK